EnliTISA Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
6
EnliTISA General Information
Description
Manufacturer of pharmaceuticals intended to develop effective therapies for inflammatory and fibrotic diseases. The company offers advanced drug research, clinical-stage development, and patented compounds, enabling healthcare providers to address unmet medical needs with safer and better-tolerated treatments.
Contact Information
Website
www.enlitisa.comCorporate Office
- Rooms 201, 202, 203, BuildingA
- Block1, Number 800, Qingdai Road, Pudong New District, Shanghai
- Shanghai, 201318
- China
Corporate Office
- Rooms 201, 202, 203, BuildingA
- Block1, Number 800, Qingdai Road, Pudong New District, Shanghai
- Shanghai, 201318
- China
EnliTISA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Early Stage VC | 26-Sep-2024 | Completed | Generating Revenue | |||
| 8. Early Stage VC | 21-Jun-2024 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A1) | 03-Mar-2024 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 31-Mar-2024 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 19-Sep-2023 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 28-Jul-2023 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 29-May-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 29-Sep-2022 | Completed | Generating Revenue | |||
| 1. Secondary Transaction - Private | 22-Jul-2022 | Completed | Generating Revenue |
EnliTISA Patents
EnliTISA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025195444-A1 | New use of peptides derived from vasoactive intestinal peptide | Pending | 20-Mar-2024 | ||
| EP-4798158-A1 | New short-chain peptides and derivatives thereof | Pending | 23-Oct-2023 | ||
| WO-2025087269-A1 | New short-chain peptides and derivatives thereof | Inactive | 23-Oct-2023 | ||
| AU-2024312518-A1 | New multi-functional oligopeptides | Pending | 22-Jun-2023 | ||
| EP-4731305-A1 | New multi-functional oligopeptides | Pending | 22-Jun-2023 | C07K7/06 |
EnliTISA Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sunbow Capital | Asset Manager | Minority | ||
| CAS Investment Management | Growth/Expansion | Minority | ||
| Step Holdings | Venture Capital | Minority | ||
| StepVC | Venture Capital | Minority | ||
| Zhangjiang Hi-Tech Park | Corporation | Minority |
EnliTISA FAQs
-
When was EnliTISA founded?
EnliTISA was founded in 2021.
-
Where is EnliTISA headquartered?
EnliTISA is headquartered in Shanghai, China.
-
What industry is EnliTISA in?
EnliTISA’s primary industry is Drug Discovery.
-
Is EnliTISA a private or public company?
EnliTISA is a Private company.
-
What is EnliTISA’s current revenue?
The current revenue for EnliTISA is .
-
Who are EnliTISA’s investors?
Sunbow Capital, CAS Investment Management, Step Holdings, StepVC, and Zhangjiang Hi-Tech Park are 5 of 6 investors who have invested in EnliTISA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process